Pliant Therapeutics Q2 2026 net loss narrows to $22.4M; FORTIFY enrollment ahead of schedule

PLIANT THERAPEUTICS, INC.

2026-Q2 EPS reported -$0.69

Q2 2026 net loss $22.4M vs $43.3M prior-year; R&D spend $16.7M vs $32.2M, G&A $7.1M vs $13.4M on bexotegrast termination and headcount cuts.
Cash, equivalents and short-term investments of $159.6M at June 30, 2026; expected to fund operations into second half of 2028.
FORTIFY Phase 1b trial of PLN-101095 enrolling ahead of schedule; up to 102 patients across 3 cohorts; interim data expected 2027.
Appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D. (Jazz Pharmaceuticals EVP R&D/CMO) to Board of Directors.
AACR data: PLN-101095 monotherapy raised IFN-γ, CXCL9 and granzyme-B only in responders, signaling T-cell reactivation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.